Human Breast Cancer miRNA PCR Array: MIHS-109Z | | |
The Human Breast Cancer miScript miRNA PCR Array profiles the expression of 84 miRNAs known or predicted to alter their expression during breast cancer initiation or progression. This array provides cancer researchers with a convenient way to quickly analyze the miRNAs most relevant to breast tumorigenesis. Breast cancer is a heterogeneous disease with multiple classifications. For example, not all breast tumors express the estrogen receptor, necessary for treatment via selective estrogen receptor modulators (SERMs). In addition, some breast cancers progress under chemotherapeutic treatment and become resistant to certain drugs. Intense research into carcinogenic mechanisms has identified dysregulated genes, either via functional defects due to somatic mutations, or gene expression alterations due to epigenetic changes. miRNAs epigenetically regulate mRNA, and therefore miRNA dysregulation will affect target mRNA expression. Microarray expression analyses of miRNA have discovered potential biomarkers of breast cancer oncogenesis, and many results have been followed up with functional studies. This array includes miRNAs that are dysregulated in estrogen receptor-responsive or drug-resistant breast tumors. miRNAs with known functions in breast cancer are included, as well as miRNAs hypothesized to be involved, either via microarray studies or as a bioinformatically-predicted regulators of known breast cancer genes. The profiling results from this array may yield insights into the molecular mechanisms behind the pathogenesis of breast cancers. A set of controls present on this array enables data analysis using the ΔΔCT method of relative quantification, assessment of reverse transcription performance, and assessment of PCR performance. Using SYBR Green-based real-time PCR, the expression of a focused panel of miRNAs related to breast cancer can be easily and reliably analyzed with this miScript miRNA PCR Array. miScript miRNA PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease. 96-well, 384-well ( 4 x 96 ), and Rotor-Disc 100 formats are available. See the complete miRNA PCR Array list | | |
| |
Potential Biomarkers:Upregulated: miR-128, miR-210.
Regulated: miR-7-5p.
Drug Resistance:Upregulated: miR-10a-5p, miR-125b-5p, miR-132-3p, miR-155-5p, miR-186-5p, miR-199a-3p // miR-199b-3p, miR-21-5p, miR-210, miR-212-3p, miR-22-3p, miR-222-3p, miR-29a-3p, miR-31-5p, miR-328.
Downregulated: miR-141-3p, miR-148a-3p, miR-152, miR-15a-5p, miR-15b-5p, miR-181d, miR-193b-3p, miR-200c-3p, miR-205-5p, miR-25-3p, miR-27b-3p, miR-485-5p, miR-489, miR-93-5p.
Regulated: miR-100-5p, miR-107, miR-130a-3p, miR-140-5p, miR-17-5p // miR-106a-5p, miR-181b-5p, miR-181c-5p, miR-182-5p, miR-206, miR-495-3p.
Estrogen Receptor-Dependent:Upregulated: miR-21-5p.
Downregulated: miR-181d, miR-193b-3p, miR-200a-3p, miR-200c-3p, miR-203a, miR-26a-5p, miR-26b-5p, miR-27a-3p, miR-27b-3p.
Regulated: let-7a-5p, let-7c, let-7f-5p, let-7g-5p, miR-181a-5p, miR-181b-5p, miR-98-5p.
miRNAs with Known Functions Related to Breast Cancer: let-7i-5p, miR-100-5p, miR-107, miR-10a-5p, miR-10b-5p, miR-125b-5p, miR-130a-3p, miR-132-3p, miR-140-5p, miR-141-3p, miR-148a-3p, miR-152, miR-155-5p, miR-15a-5p, miR-15b-5p, miR-16-5p, miR-17-5p // miR-106a-5p, miR-181d, miR-182-5p, miR-186-5p, miR-193b-3p, miR-199a-3p // miR-199b-3p, miR-200b-3p, miR-200c-3p, miR-204-5p, miR-205-5p, miR-206, miR-21-5p, miR-210, miR-212-3p, miR-22-3p, miR-222-3p, miR-25-3p, miR-27a-3p, miR-27b-3p, miR-29a-3p, miR-31-5p, miR-328, miR-429, miR-485-5p, miR-489, miR-495-3p, miR-7-5p, miR-93-5p, miR-96-5p.
miRNAs Predicted to Regulate Breast Cancer Genes: miR-1, miR-129-5p, miR-195-5p, miR-340-5p, miR-548c-3p, miR-607, miR-613.
Other miRNAs: let-7b-5p, let-7d-5p, let-7e-5p, miR-125b-1-3p, miR-130b-3p, miR-145-5p, miR-18a-5p, miR-19a-3p, miR-19b-3p, miR-199a-5p, miR-20a-5p, miR-20b-5p, miR-202-3p, miR-214-3p, miR-223-3p, miR-29b-3p, miR-29c-3p, miR-424-5p, miR-497-5p.